Affiliation:
1. Center for Medical Research, Medical University of Graz, 8010 Graz, Austria
2. Research Center Pharmaceutical Engineering GmbH, 8010 Graz, Austria
Abstract
The respiratory barrier, a thin epithelial barrier that separates the interior of the human body from the environment, is easily damaged by toxicants, and chronic respiratory diseases are common. It also allows the permeation of drugs for topical treatment. Animal experimentation is used to train medical technicians, evaluate toxicants, and develop inhaled formulations. Species differences in the architecture of the respiratory tract explain why some species are better at predicting human toxicity than others. Some species are useful as disease models. This review describes the anatomical differences between the human and mammalian lungs and lists the characteristics of currently used mammalian models for the most relevant chronic respiratory diseases (asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary hypertension, pulmonary fibrosis, and tuberculosis). The generation of animal models is not easy because they do not develop these diseases spontaneously. Mouse models are common, but other species are more appropriate for some diseases. Zebrafish and fruit flies can help study immunological aspects. It is expected that combinations of in silico, in vitro, and in vivo (mammalian and invertebrate) models will be used in the future for drug development.
Funder
The Research Center Pharmaceutical Engineering
Austrian Federal Ministry of Transport, Innovation and Technology
Austrian Federal Ministry of Economy, Family and Youth
State of Styria
Austrian Research Promotion Agency FFG
Reference219 articles.
1. OECD (2018). OECD Guidelines on the Testing of Chemicals, OECD. 28-Day (Subacute) Inhalation Toxicity Study. No. 412.
2. Fitzgerald, D., and Creaner, G. (2023, November 11). Pharmaceutical Regulations, Organizations and Quality Standards You Must Know to Make Safe Medicines and Medical Devices. GetReskilled. Available online: https://www.getreskilled.com/pharmaceutical-companies/regulations/.
3. Consider drug efficacy before first-in-human trials;Kimmelman;Nature,2017
4. Marshall, L.J., Constantino, H., and Seidle, T. (2022). Phase-In to Phase-Out-Targeted, Inclusive Strategies Are Needed to Enable Full Replacement of Animal Use in the European Union. Animals, 12.
5. Animal testing and medicine;Hajar;Heart Views,2011
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献